
|Articles|July 6, 2012
Impact on Daily Practice Is Completely Unknown
Author(s)Lawrence D. Wagman, MD, FACS
For independent physician practices, the realities of overhead expenses, time available for patient care, and regulatory requirements can only be assessed when the specific requirements for reporting and reimbursement are clear.
Advertisement
Array
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
2
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
3
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
4
What Were The Most Impactful GU Oncology Data From ESMO 2025?
5





![“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma," according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png?w=350&fit=crop&auto=format)













































































